Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

26 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Efficacy and safety of ligelizumab in adults and adolescents with chronic spontaneous urticaria: results of two phase 3 randomised controlled trials.
Maurer M, Ensina LF, Gimenez-Arnau AM, Sussman G, Hide M, Saini S, Grattan C, Fomina D, Rigopoulos D, Berard F, Canonica GW, Rockmann H, Irani C, Szepietowski JC, Leflein J, Bernstein JA, Peter JG, Kulthanan K, Godse K, Ardusso L, Ukhanova O, Staubach P, Sinclair R, Gogate S, Thomsen SF, Tanus T, Ye YM, Burciu A, Barve A, Modi D, Scosyrev E, Hua E, Letzelter K, Varanasi V, Patekar M, Severin T; PEARL-1 and PEARL-2 trial investigators. Maurer M, et al. Among authors: leflein j. Lancet. 2024 Jan 13;403(10422):147-159. doi: 10.1016/S0140-6736(23)01684-7. Epub 2023 Nov 23. Lancet. 2024. PMID: 38008109 Clinical Trial.
Benralizumab does not elicit therapeutic effect in patients with chronic spontaneous urticaria: results from the phase 2b multinational, randomised, double-blind, placebo-controlled ARROYO trial.
Altrichter S, Giménez-Arnau AM, Bernstein JA, Metz M, Bahadori L, Bergquist M, Brooks L, Ho CN, Jain P, Lukka PB, Rodriguez-Suárez E, Walton C, Datto CJ; ARROYO Study Investigators. Altrichter S, et al. Br J Dermatol. 2024 Feb 17:ljae067. doi: 10.1093/bjd/ljae067. Online ahead of print. Br J Dermatol. 2024. PMID: 38367194
Lack of effect of benralizumab on signs and symptoms of moderate-to-severe atopic dermatitis: Results from the phase 2 randomized, double-blind, placebo-controlled HILLIER trial.
Guttman-Yassky E, Bahadori L, Brooks L, Clark KL, Grindebacke H, Ho CN, Katial R, Pham TH, Walton C, Datto CJ; HILLIER study group†. Guttman-Yassky E, et al. J Eur Acad Dermatol Venereol. 2023 Oct;37(10):e1211-e1214. doi: 10.1111/jdv.19195. Epub 2023 Jun 12. J Eur Acad Dermatol Venereol. 2023. PMID: 37178404 Clinical Trial. No abstract available.
Severe Asthma Standard-of-Care Background Medication Reduction With Benralizumab: ANDHI in Practice Substudy.
Louis R, Harrison TW, Chanez P, Menzella F, Philteos G, Cosio BG, Lugogo NL, de Luiz G, Burden A, Adlington T, Keeling N, Kwiatek J, Garcia Gil E; ANDHI Study Investigators. Louis R, et al. J Allergy Clin Immunol Pract. 2023 Jun;11(6):1759-1770.e7. doi: 10.1016/j.jaip.2023.03.009. Epub 2023 Mar 21. J Allergy Clin Immunol Pract. 2023. PMID: 36948488 Free article.
Dupilumab in children aged 6 months to younger than 6 years with uncontrolled atopic dermatitis: a randomised, double-blind, placebo-controlled, phase 3 trial.
Paller AS, Simpson EL, Siegfried EC, Cork MJ, Wollenberg A, Arkwright PD, Soong W, Gonzalez ME, Schneider LC, Sidbury R, Lockshin B, Meltzer S, Wang Z, Mannent LP, Amin N, Sun Y, Laws E, Akinlade B, Dillon M, Kosloski MP, Kamal MA, Dubost-Brama A, Patel N, Weinreich DM, Yancopoulos GD, O'Malley JT, Bansal A; participating investigators. Paller AS, et al. Lancet. 2022 Sep 17;400(10356):908-919. doi: 10.1016/S0140-6736(22)01539-2. Lancet. 2022. PMID: 36116481 Clinical Trial.
Onset of effect and impact on health-related quality of life, exacerbation rate, lung function, and nasal polyposis symptoms for patients with severe eosinophilic asthma treated with benralizumab (ANDHI): a randomised, controlled, phase 3b trial.
Harrison TW, Chanez P, Menzella F, Canonica GW, Louis R, Cosio BG, Lugogo NL, Mohan A, Burden A, McDermott L, Garcia Gil E, Zangrilli JG; ANDHI study investigators. Harrison TW, et al. Lancet Respir Med. 2021 Mar;9(3):260-274. doi: 10.1016/S2213-2600(20)30414-8. Epub 2020 Dec 22. Lancet Respir Med. 2021. PMID: 33357499 Clinical Trial.
ATDC mediates a TP63-regulated basal cancer invasive program.
Palmbos PL, Wang Y, Bankhead Iii A, Kelleher AJ, Wang L, Yang H, Ahmet ML, Gumkowski ER, Welling SD, Magnuson B, Leflein J, Lorenzatti Hiles G, Abel EV, Dziubinski ML, Urs S, Day ML, Ljungman ME, Simeone DM. Palmbos PL, et al. Among authors: leflein j. Oncogene. 2019 May;38(18):3340-3354. doi: 10.1038/s41388-018-0646-9. Epub 2019 Jan 14. Oncogene. 2019. PMID: 30643195 Free PMC article.
Safety of Adding Salmeterol to Fluticasone Propionate in Children with Asthma.
Stempel DA, Szefler SJ, Pedersen S, Zeiger RS, Yeakey AM, Lee LA, Liu AH, Mitchell H, Kral KM, Raphiou IH, Prillaman BA, Buaron KS, Yun Kirby S, Pascoe SJ; VESTRI Investigators. Stempel DA, et al. N Engl J Med. 2016 Sep 1;375(9):840-9. doi: 10.1056/NEJMoa1606356. N Engl J Med. 2016. PMID: 27579634 Free article. Clinical Trial.
ATDC/TRIM29 Drives Invasive Bladder Cancer Formation through miRNA-Mediated and Epigenetic Mechanisms.
Palmbos PL, Wang L, Yang H, Wang Y, Leflein J, Ahmet ML, Wilkinson JE, Kumar-Sinha C, Ney GM, Tomlins SA, Daignault S, Kunju LP, Wu XR, Lotan Y, Liebert M, Ljungman ME, Simeone DM. Palmbos PL, et al. Among authors: leflein j. Cancer Res. 2015 Dec 1;75(23):5155-66. doi: 10.1158/0008-5472.CAN-15-0603. Epub 2015 Oct 15. Cancer Res. 2015. PMID: 26471361 Free PMC article.
ATDC induces an invasive switch in KRAS-induced pancreatic tumorigenesis.
Wang L, Yang H, Abel EV, Ney GM, Palmbos PL, Bednar F, Zhang Y, Leflein J, Waghray M, Owens S, Wilkinson JE, Prasad J, Ljungman M, Rhim AD, Pasca di Magliano M, Simeone DM. Wang L, et al. Among authors: leflein j. Genes Dev. 2015 Jan 15;29(2):171-83. doi: 10.1101/gad.253591.114. Genes Dev. 2015. PMID: 25593307 Free PMC article.
26 results